Soleno Therapeutics Future Growth

Future criteria checks 3/6

Soleno Therapeutics se prevé un crecimiento anual de los beneficios y los ingresos de 74.4% y 76.7%, respectivamente, mientras que el BPA aumentará de grow a 75.1%.

Key information

60.3%

Earnings growth rate

62.5%

EPS growth rate

Biotechs earnings growth	20.9%
Revenue growth rate	54.4%
Future return on equity	n/a
Analyst coverage	Good
Last updated	21 Mar 2024

Recent future growth updates

Recent updates

We're Not Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn

Mar 08

Here's Why We're Watching Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation

Sep 20

Soleno sheds 13% as 1-for-15 reverse stock split takes effect

Aug 26

Companies Like Soleno Therapeutics (NASDAQ:SLNO) Could Be Quite Risky

Aug 12

Soleno Therapeutics surges 49% on regulatory pathway for Prader-Willi syndrome treatment

Jul 20

Here's Why Soleno Therapeutics (NASDAQ:SLNO) Must Use Its Cash Wisely

May 10

We're A Little Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Rate

Jan 24

Soleno shares soar on FDA Orphan Drug status for Glycogen Storage Disease treatment

Jun 02

Will Soleno Therapeutics (NASDAQ:SLNO) Spend Its Cash Wisely?

Mar 23

Need To Know: Soleno Therapeutics, Inc. (NASDAQ:SLNO) Insiders Have Been Buying Shares

Jan 29

Soleno Therapeutics: Could Be Big Fish In The Small Pond

Jan 08

Here's Why We're Not Too Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation

Dec 07

Earnings and Revenue Growth Forecasts

NasdaqCM:SLNO - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	151	39	67	N/A	5
12/31/2025	45	-31	-1	-38	6
12/31/2024	N/A	-58	-40	-47	6
12/31/2023	N/A	-39	-25	-25	N/A
9/30/2023	N/A	-33	-24	-24	N/A
6/30/2023	N/A	-28	-22	-22	N/A
3/31/2023	N/A	-27	-21	-21	N/A
12/31/2022	N/A	-24	-21	-21	N/A
9/30/2022	N/A	-21	-23	-23	N/A
6/30/2022	N/A	-23	-23	-23	N/A
3/31/2022	N/A	-28	-27	-27	N/A
12/31/2021	N/A	-31	-28	-28	N/A
9/30/2021	N/A	-31	-28	-28	N/A
6/30/2021	N/A	-31	-29	-29	N/A
3/31/2021	N/A	-28	-27	-27	N/A
12/31/2020	N/A	-25	-25	-25	N/A
9/30/2020	N/A	-36	-23	-23	N/A
6/30/2020	N/A	-27	-22	-22	N/A
3/31/2020	N/A	-30	-19	-19	N/A
12/31/2019	N/A	-31	-17	-17	N/A
9/30/2019	N/A	-16	-16	-16	N/A
6/30/2019	N/A	-19	-14	-14	N/A
3/31/2019	N/A	-16	-13	-13	N/A
12/31/2018	N/A	-12	-12	-12	N/A
9/30/2018	N/A	-16	-11	-11	N/A
6/30/2018	N/A	-17	-10	-10	N/A
3/31/2018	N/A	-13	-10	-10	N/A
12/31/2017	N/A	-12	-10	-10	N/A
9/30/2017	N/A	-13	N/A	-10	N/A
6/30/2017	0	-11	N/A	-11	N/A
3/31/2017	0	-9	N/A	-12	N/A
12/31/2016	N/A	-10	N/A	-13	N/A
9/30/2016	0	-8	N/A	-14	N/A
6/30/2016	0	-10	N/A	-14	N/A
3/31/2016	1	-7	N/A	-12	N/A
12/31/2015	N/A	-10	N/A	-10	N/A
9/30/2015	0	-20	N/A	-8	N/A
6/30/2015	0	-19	N/A	-7	N/A
3/31/2015	0	-24	N/A	-6	N/A
12/31/2014	N/A	-13	N/A	-4	N/A
9/30/2014	N/A	-7	N/A	-4	N/A
6/30/2014	N/A	-6	N/A	-3	N/A
3/31/2014	N/A	-6	N/A	-3	N/A
12/31/2013	3	-4	N/A	-1	N/A

Analyst Future Growth Forecasts

Ingresos vs. tasa de ahorro: SLNO se prevé que sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.2%).

Beneficios frente mercado: SLNO se prevé que sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: SLNO se espera que sea rentable en los próximos 3 años.

Ingresos vs. Mercado: SLNO no tendrá ingresos el año que viene.

Ingresos de alto crecimiento: SLNO no tendrá ingresos el año que viene.

Earnings per Share Growth Forecasts

Future Return on Equity

Futura rentabilidad financiera (ROE): Datos insuficientes para determinar si la Rentabilidad de los fondos propios de SLNO se prevé elevada dentro de 3 años.

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Soleno Therapeutics Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Price target increased by 19% to US$60.17

Forecast to breakeven in 2026

Price target increased by 23% to US$45.67

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2025

Recent updates

We're Not Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn

Price target increased by 19% to US$60.17

Soleno Therapeutics Strengthens Leadership Team with Key Appointments

Forecast to breakeven in 2026

Vice President of Clinical Operations notifies of intention to sell stock

President recently sold US$3.3m worth of stock

President notifies of intention to sell stock

President recently sold US$1.5m worth of stock

Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open Label Study of DCCR in Prader-Willi Syndrome

Price target increased by 23% to US$45.67

Soleno Therapeutics, Inc. announced that it has received $59.98825 million in funding

New major risk - Shareholder dilution

Soleno Therapeutics, Inc. announced that it expects to receive $30 million in funding

Soleno Therapeutics, Inc. Announces Positive Statistically Significant Top-Line Results from Randomized Withdrawal Period of Study C602 of Dccr for Prader-Willi Syndrome

Here's Why We're Watching Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation

Soleno Therapeutics Appoints Matthew Pauls to Board of Directors

New major risk - Financial position

No longer forecast to breakeven

No longer forecast to breakeven

Soleno Therapeutics, Inc. announced that it has received $10.000044 million in funding from Abingworth LLP, Vivo Capital, LLC, Nantahala Capital Management, LLC, Brightleaf Capital, Corbin Capital Partners, L.P.

Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome

Soleno Therapeutics, Inc. Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome

Forecast to breakeven in 2025

Soleno Therapeutics, Inc. announced that it expects to receive $59.89 million in funding from Abingworth LLP, Vivo Capital, LLC, Nantahala Capital Management, LLC, Brightleaf Capital, Corbin Capital Partners, L.P.

Price target decreased to US$9.00

Insufficient new directors

Soleno Therapeutics, Inc. Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome

Soleno sheds 13% as 1-for-15 reverse stock split takes effect

Companies Like Soleno Therapeutics (NASDAQ:SLNO) Could Be Quite Risky

Insufficient new directors

Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics surges 49% on regulatory pathway for Prader-Willi syndrome treatment

Insufficient new directors

Here's Why Soleno Therapeutics (NASDAQ:SLNO) Must Use Its Cash Wisely

Price target decreased to US$5.00

Soleno Therapeutics, Inc., Annual General Meeting, Jun 01, 2022

Soleno Therapeutics Provides Regulatory Update on Dccr for the Treatment of Prader-Willi Syndrome

We're A Little Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Rate

Soleno Therapeutics Announces Positive Data Showing Continued Significant Improvements in Symptoms of Pws Following One Year Treatment with Dccr

Soleno Therapeutics, Inc.(NasdaqCM:SLNO) dropped from Russell 3000E Growth Index

Soleno Therapeutics Receives Orphan Drug Designation from FDA for Diazoxide Choline for the Treatment of Glycogen Storage Disease Type 1A

Soleno shares soar on FDA Orphan Drug status for Glycogen Storage Disease treatment

Soleno Therapeutics Announces Presentation of Positive Behavioral Data from Ongoing Extension Study of DCCR for Treatment of Prader-Willi Syndrome

Will Soleno Therapeutics (NASDAQ:SLNO) Spend Its Cash Wisely?

Soleno Therapeutics, Inc. Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

Price target lowered to US$7.00

New 90-day low: US$1.38

Soleno Therapeutics Announces Collaboration with Vanderbilt University to Discover and Develop Next Generation K(ATP) Channel Activators for the Treatment of Rare Diseases

Soleno Therapeutics, Inc. Provides Recap of Key Opinion Leader Webinar on DCCR for Treatment of Prader-Willi Syndrome

New 90-day high: US$2.74

Need To Know: Soleno Therapeutics, Inc. (NASDAQ:SLNO) Insiders Have Been Buying Shares

Soleno Therapeutics: Could Be Big Fish In The Small Pond

New 90-day high: US$2.10

Soleno Therapeutics Provides Regulatory Update on Dccr for the Treatment of Prader-Willi Syndrome

Here's Why We're Not Too Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation

Soleno Therapeutics Announces Presentation of Body Composition Results from DESTINY PWS, a Phase III Trial of DCCR in Prader-Willi Syndrome

Soleno Therapeutics, Inc. Announces the Body Composition Data from the Company’s Phase III trial, DESTINY PWS (C601)

New 90-day low: US$1.62

Soleno Therapeutics, Inc. Announces Appointment of Andrew Sinclair in Board of Directors

Soleno Therapeutics Announces Updated Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome

New 90-day high: US$2.51

New 90-day low - US$1.71

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies